178P PD-L1 expression in ER-low versus triple-negative (TN) advanced breast cancer (aBC), and according to phenotypic evolution from primary to recurrent disease

Autor: Miglietta, F., Nicolè, L., Iannaccone, D., Giarratano, T., Massa, D., Griguolo, G., Giorgi, C.A., Righetto, A., Girardi, F., Zurlo, C., Porra, F., Zanghi, F., Vernaci, G., Fassan, M., Guarneri, V., Dieci, M.V.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S287-S287

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.

Autor: Vernaci G; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Savarino EV; Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.; Gastroenterology Unit, Azienda Ospedale Università di Padova, Padova, Italy., Patuzzi I; Research & Development, Eubiome Srl, Padova, Italy., Facchin S; Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.; Gastroenterology Unit, Azienda Ospedale Università di Padova, Padova, Italy., Zingone F; Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.; Gastroenterology Unit, Azienda Ospedale Università di Padova, Padova, Italy., Massa D; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy., Faggioni G; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Giarratano T; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Miglietta F; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy., Griguolo G; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy., Fassan M; Department of Medicine, Surgical Pathology Unit, University of Padua, Padua, Italy.; Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy., Lo Mele M; Department of Pathology, Azienda Ospedale Università Padova, Padova, Italy., Gasparini E; Breast Cancer Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.; Oncology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy., Bisagni G; Breast Cancer Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.; Oncology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy., Guarneri V; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy., Dieci MV; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

Publikováno v: The oncologist [Oncologist] 2023 Sep 07; Vol. 28 (9), pp. e703-e711.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment.

Autor: Miglietta F; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35128, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128, Padova, Italy., Griguolo G; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35128, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128, Padova, Italy., Bottosso M; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35128, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128, Padova, Italy., Giarratano T; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128, Padova, Italy., Lo Mele M; Surgical Pathology Unit, University Hospital of Padua, 35121, Padua, Italy., Fassan M; Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, 35121, Padua, Italy.; Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy., Cacciatore M; Department of Pathology and Molecular Genetics, Treviso General Hospital, Treviso, Italy., Genovesi E; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35128, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128, Padova, Italy., De Bartolo D; Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, 35121, Padua, Italy., Vernaci G; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35128, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128, Padova, Italy., Amato O; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35128, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128, Padova, Italy., Porra F; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35128, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128, Padova, Italy., Conte P; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35128, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128, Padova, Italy., Guarneri V; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35128, Padova, Italy. valentina.guarneri@unipd.it.; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128, Padova, Italy. valentina.guarneri@unipd.it., Dieci MV; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35128, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128, Padova, Italy.

Publikováno v: NPJ breast cancer [NPJ Breast Cancer] 2022 May 20; Vol. 8 (1), pp. 66. Date of Electronic Publication: 2022 May 20.

212P HER2-low breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment

Autor: Miglietta, F., Griguolo, G., Bottosso, M., Giarratano, T., Lo Mele, M., Fassan, M., Cacciatore, M., Genovesi, E., De Bartolo, D., Vernaci, G., Amato, O., Porra, F., Conte, P.F., Guarneri, V., Dieci, M.V.

Publikováno v: In Annals of Oncology September 2021 32 Supplement 5:S451-S451